Co-expression of the CD98hc/LAT1 complex correlates with endocrine therapy resistance in patients with estrogen receptor (ER) positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. Here, SLC3A2 is linked to breast carcinoma.